HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Center, on November 9, 2024, in Houston, Texas.
The presentation will focus on updated results in PD-L1 CPS ≥20 patients receiving the combination treatment. The poster will be accessible on HOOKIPA's website under the Scientific Publications section.
HOOKIPA Pharma (NASDAQ: HOOK) ha annunciato che i dati aggiornati della Fase 2 per eseba-vec (HB200) in combinazione con pembrolizumab nel trattamento di prima linea per il cancro della testa e del collo HPV16-positivo recidivante/metastatico saranno presentati al SITC 2024. La presentazione sarà effettuata come poster con aggiornamenti tardivi dal Dr. Alan Ho, Capo del Servizio di Oncologia della Testa e del Collo presso il Memorial Sloan Cancer Center, il 9 novembre 2024, a Houston, Texas.
La presentazione si concentrerà sui risultati aggiornati nei pazienti con un punteggio PD-L1 CPS ≥20 che ricevono il trattamento combinato. Il poster sarà accessibile sul sito web di HOOKIPA nella sezione Pubblicazioni Scientifiche.
HOOKIPA Pharma (NASDAQ: HOOK) anunció que se presentarán datos actualizados de la Fase 2 para eseba-vec (HB200) más pembrolizumab en cáncer de cabeza y cuello HPV16-positivo recurrente/metastásico en primera línea en el SITC 2024. La presentación se realizará como un póster de última hora por el Dr. Alan Ho, Jefe del Servicio de Oncología de Cabeza y Cuello en el Memorial Sloan Cancer Center, el 9 de noviembre de 2024, en Houston, Texas.
La presentación se centrará en los resultados actualizados de pacientes con PD-L1 CPS ≥20 que reciben el tratamiento combinado. El póster estará disponible en el sitio web de HOOKIPA en la sección de Publicaciones Científicas.
HOOKIPA Pharma (NASDAQ: HOOK)은 SITC 2024에서 HPV16 양성 재발/전이성 두경부암의 1차 치료로서 eseba-vec (HB200)와 pembrolizumab의 2상 데이터가 업데이트되어 발표될 것이라고 발표했습니다. 이 발표는 2024년 11월 9일에 텍사스 휴스턴에서 Memorial Sloan Cancer Center의 두경부 종양학 서비스 수장인 Alan Ho 박사가 업데이트 포스터로 발표할 예정입니다.
발표는 조합 치료를 받는 PD-L1 CPS ≥20 환자의 업데이트된 결과에 초점을 맞출 것입니다. 포스터는 HOOKIPA의 웹사이트에서 과학 출판물 섹션에서 접근할 수 있습니다.
HOOKIPA Pharma (NASDAQ: HOOK) a annoncé que des données mises à jour de la Phase 2 pour eseba-vec (HB200) en combinaison avec pembrolizumab dans le cancer de la tête et du cou HPV16-positif récidivant/métastatique en première ligne seront présentées au SITC 2024. La présentation sera faite sous forme de poster de dernière minute par le Dr Alan Ho, Chef du Service d'Oncologie de la Tête et du Cou au Memorial Sloan Cancer Center, le 9 novembre 2024, à Houston, Texas.
La présentation se concentrera sur les résultats mis à jour chez les patients avec un CPS PD-L1 ≥20 recevant le traitement combiné. Le poster sera accessible sur le site web de HOOKIPA dans la section Publications Scientifiques.
HOOKIPA Pharma (NASDAQ: HOOK) hat angekündigt, dass aktualisierte Phase 2-Daten für eseba-vec (HB200) plus Pembrolizumab zur Erstlinientherapie bei rezidivierenden/metastatischen HPV16-positiven Kopf-Hals-Krebs am SITC 2024 präsentiert werden. Die Präsentation wird am 9. November 2024 in Houston, Texas, als verspätetes Poster von Dr. Alan Ho, dem Leiter des Kopf-Hals-Onkologie-Dienstes im Memorial Sloan Cancer Center, durchgeführt.
Der Fokus der Präsentation liegt auf den aktualisierten Ergebnissen bei Patienten mit PD-L1 CPS ≥20, die die Kombinationstherapie erhalten. Das Poster wird auf der Website von HOOKIPA im Bereich Wissenschaftliche Veröffentlichungen verfügbar sein.
- None.
- None.
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024
NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented as a late-breaking poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), taking place in Houston, Texas from November 8-10, 2024.
The poster will be presented by Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Cancer Center (MSKCC), a clinical collaborator of HOOKIPA.
Details of the poster presentation are:
Abstract Title: Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients
Presenter: Dr. Alan Ho, MSKCC
Session Date: Saturday, November 9, 2024
Session Time: 9:00 AM – 8:00 PM CDT
Late Breaking Abstract Number: 1480
The poster will be available on November 9, 2024 on the HOOKIPA website on the “Scientific Publications” tab of the “Our Science” page.
About Eseba-vec
Eseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. The first indication for eseba-vec is for the potential treatment of patients with HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma (R/M OPSCC) with a PDL1 CPS of 20 or higher, in combination with pembrolizumab, in the first line (1L) setting. Eseba-vec has received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency for the treatment of 1L HPV16+ OPSCC. Eseba-vec was developed using HOOKIPA’s proprietary arenavirus platform.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing next generation immunotherapeutics based on its proprietary arenavirus platform. The company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. HOOKIPA’s pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, HOOKIPA has partnered with Gilead to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Find out more about HOOKIPA online at www.hookipapharma.com.
Availability of Other Information About HOOKIPA
Investors and others should note that we announce material financial information to our investors using our investor relations website, www.ir.hookipapharma.com, SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website.
Forward Looking Statements
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “anticipates”, “believes”, “expects”, “plans”, “potential”, “will”, “would” or similar expressions and the negative of those terms. Forward-looking statements in this press release include HOOKIPA’s statements regarding the potential of its product candidates to improve the care of the patients it seeks to treat. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, plans and timelines for the preclinical and clinical development of its product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs, the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including those for eseba-vec, HB-700, HB-400 and HB-500, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, and HOOKIPA’s ability to continue as a going concern and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see HOOKIPA’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at https://sec.gov and HOOKIPA’s website at www.hookipapharma.com. All information in this press release is as of the date of the release, and HOOKIPA undertakes no duty to update this information unless required by law.
For further information, please contact:
Investors
Chuck Padala
Chuck@LifeSciAdvisors.com
FAQ
When will HOOKIPA Pharma (HOOK) present its eseba-vec Phase 2 data at SITC 2024?
What is the focus of HOOKIPA Pharma's (HOOK) late-breaking presentation at SITC 2024?
Who will present HOOKIPA Pharma's (HOOK) research at SITC 2024?
Where can investors find HOOKIPA Pharma's (HOOK) SITC 2024 poster after the presentation?
